Skip to content
Study details
Enrolling now

Decitabine and Ruxolitinib for Myelofibrosis

University of Washington
NCT IDNCT04282187ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

25

Study length

about 6.6 years

Ages

18+

Locations

1 site in WA

What this study is about

This trial is testing whether decitabine with ruxolitinib works before a stem cell transplant in treating myelofibrosis. The goal is to see if this treatment helps stop the growth of cancer cells in the bone marrow, improving blood counts and overall health.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Questionnaire Administration
  • 2.Take Decitabine
  • 3.Take Fedratinib
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

decitabine, fedratinib, pacritinib, ruxolitinib

Drug routes

injection, intravenous, oral (Oral Capsule), oral (Oral Tablet)

Endpoints

Secondary: Overall survival, Overall survival regardless of transplant status, Relapse-free survival, Relapse-free survival regardless of transplant status

Procedures

diagnostic

Body systems

Oncology